GV1001 Placebo

DRUG5 trials

Sponsors

GemVax & Kael, Samsung Pharmaceutical Co., Ltd.

Conditions

Benign Prostatic Hyperplasia (BPH)Mild to Moderate Alzheimer's DiseaseModerate to Severe Alzheimer's DiseaseProgressive Supranuclear Palsy

Phase 2

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

CompletedNCT05189210

GemVax & KaelMild to Moderate Alzheimer's Disease

Start: 2022-10-05End: 2025-04-16Updated: 2025-09-04

GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

CompletedNCT05819658

GemVax & KaelProgressive Supranuclear Palsy

Start: 2023-06-14End: 2024-10-11Updated: 2026-02-10

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

CompletedNCT06235775

GemVax & KaelProgressive Supranuclear Palsy

Start: 2023-12-12End: 2025-09-01Updated: 2025-11-21

Phase 3

Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

CompletedNCT04032067

GemVax & KaelBenign Prostatic Hyperplasia (BPH)

Start: 2019-10-30End: 2022-03-17Updated: 2022-08-25

GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)

Not yet recruitingNCT05303701

Samsung Pharmaceutical Co., Ltd.Moderate to Severe Alzheimer's Disease

Start: 2027-07-01End: 2031-07-01Target: 750Updated: 2026-06-10